Digital Repository

Novel therapies in clinical use for the management of hyperlipidaemia

Show simple item record

dc.contributor.author Mettananda, C.
dc.date.accessioned 2023-11-09T04:49:05Z
dc.date.available 2023-11-09T04:49:05Z
dc.date.issued 2023
dc.identifier.citation Asian Journal of Internal Medicine.2023;2(2):35-38 en_US
dc.identifier.issn 2827-7260 (Print)
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/27035
dc.description Not Indexed en_US
dc.description.abstract Optimal control of low-density lipoprotein cholesterol (LDLc) is identified as a major target in reducing cardiovascular disease burden globally. However, existing lipid-lowering therapies have not been able to achieve LDLc targets even in developed countries. Therefore, novel therapies for the management of hyperlipidaemia are being trialled. Currently, there are three main groups of newer medicines; bempedoic acid, PCSK9 inhibitors and inclisiran, in addition to statins and ezetimibe in use for the management of hyperlipidaemia. This article aims to introduce these newer medicines and their clinical use in the treatment of hyperlipidaemia. en_US
dc.language.iso en en_US
dc.publisher Sri Lanka College of Internal Medicine en_US
dc.subject Novel therapies en_US
dc.subject Hyperlipidaemia en_US
dc.subject LDL en_US
dc.subject Bempedoic acid en_US
dc.subject PCSK9 inhibitors en_US
dc.subject Inclisiran en_US
dc.subject siMRNA en_US
dc.title Novel therapies in clinical use for the management of hyperlipidaemia en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account